Navigation Links
Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
Date:8/30/2013

MINNEAPOLIS/ST. PAUL (08/30/2013) A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).

The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found "online first" in the journal Antiviral Chemistry & Chemotherapy.

"If you have a condition that requires you to take a medication everyday, as many patients with HIV do, you wouldn't want to have to take that medication via daily injection," said Steven Patterson, Ph.D., professor at the Center for Drug Design at the University of Minnesota. "This finding is a big step in demonstrating this treatment could be taken as a pill, similar to other HIV drugs, and is suitable for eventual clinical translation."

University of Minnesota researchers first announced decitabine and gemcitabine could potentially combine to treat HIV in research published in August 2010. The drug combination was shown to work by lethal mutagenesis that could obliterate HIV by causing the virus to mutate to a point where it was no longer infectious. For some patients, HIV's ability to quickly mutate and evolve can result in drug resistance. For patients who have developed resistance to currently available HIV treatments, the decitabine-gemcitabine drug combination could prove an effective alternative and secondary line of defense.

In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.

"There's still a lot of work that needs to be done to demonstrate the safety and efficacy of this drug combination before human clinical trials can begin," said Patterson. "But we're optimistic that we're moving forward."


'/>"/>

Contact: Miranda Taylor
tayl0551@umn.edu
612-626-2767
University of Minnesota Academic Health Center
Source:Eurekalert

Related biology news :

1. Keck award enables Carnegie Mellon and Stanford to dramatically expand crowdsourced RNA design
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Research is ensuring stormwater systems are designed for the future
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. African scientist, designer partner to fashion anti-malaria garment that wards off bugs
6. Portable diagnostics designed to be shaken, not stirred
7. MIT-designed cooler preserves tuberculosis drugs, records doses
8. Progress in Osteoporosis re-launched with new design, now invites commentary
9. Faster, cheaper gas and liquid separation using custom designed and built mesoscopic structures
10. SACLA draws acclaim for unique XFEL design
11. A new type of data papers designed to publish online interactive keys identifying biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... 2017  Genisphere LLC, provider of the 3DNA ... collaborative and sponsored research agreement with the University ... The overall goal of the partnership is to ... designs and formulations after in vivo ... vasculature as well as inflammatory responses, demonstrating various ...
(Date:4/25/2017)... ... April 25, 2017 , ... Franz Inc ... (CL) development tools, and market leader for Semantic Graph Database technology, ... available within the most effective system for developing and deploying applications to solve ...
(Date:4/25/2017)... 25, 2017 Providence ... its novel immune-modulating technology to an undisclosed global pharmaceutical ... Tregitopes, pronounced T·rej·itopes, are a set ... EpiVax CEO Annie De Groot and ... G, an autoimmune disease therapy, Tregitopes are capable ...
(Date:4/25/2017)... Gatos, California (PRWEB) , ... April 25, 2017 ... ... business, Analytical Services and Metrology Partners.     , Covalent’s Analytical Services unit ... Most samples can be measured within 24 hours of receipt. There are no ...
Breaking Biology Technology: